Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brensocatib and Midazolam DDI Study in Healthy Participants
NCT07859007Phase 1Not yet recruiting
- Sponsor
- Insmed Incorporated
- Start
- Oct 2026
- Primary completion
- Nov 2026
01
Overview
Phase 1, open-label, single-arm trial of brensocatib in bronchiectasis, sponsored by Insmed Incorporated. Primary endpoint: Plasma Concentration of Midazolam and its Metabolite. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
brensocatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT07859007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07859007.